Yong Xu of the University of South Florida, Sadaf Farooqi of University of Cambridge and Tiago Branco of University College ...

A new partnership between Walmart and drug maker Eli Lily will make it easier for people to access the super-popular weight loss drug Zepbound. Starting in mid-November, customers with a prescription ...

Direct-to-consumer (DTC) telehealth companies remove barriers to care, but questions remain regarding patient safety and proper information.

The idea was beautifully simple. One pill taken daily to melt away those excess pounds. The new breed of GLP-1 oral ...

Insurance data reveals dramatic regional differences in Ozempic and Mounjaro usage, with obesity-heavy states prescribing GLP ...

For 60 years, HSL was known for releasing energy from fat, but people born without it lose fat instead of gaining weight—a mystery that Prof. Langin and colleagues have now solved. After six decades ...

COULD ACTUALLY BE MUCH MORE ACCURATE. A MARY SALADNA IS IN THE NEWSROOM AND MARY THE RESULTS AREN’T GOOD. NO, THEY’RE NOT, BUT THE RESULTS ARE MORE REALISTIC AND MORE PROOF THAT BODY COMPOSITION ...

The prevalence of obesity in the United States could rise sharply under a definition of obesity released earlier this year by the Lancet Diabetes and Endocrinology Commission. Additionally, the ...

(NEXSTAR) — The number of states with high adult obesity rates has dropped for the first time in more than a decade, a new report released Thursday found. The nonprofit Trust for America’s Health ...

A gene that causes obesity is paradoxically linked to a reduced risk of having heart disease and high cholesterol, according to an analysis of thousands of people with obesity. “Although the obesity ...

A large proportion of the population has abdominal obesity despite a normal BMI, and these individuals are at increased cardiometabolic risk, two new studies found. “Individuals with normal BMI but ...

With the supply of GLP-1 medications finally stabilizing as their use skyrocketed 600% among Americans from 2018 to 2024, the pharmaceutical landscape for anti-obesity medications is now poised to ...